Special Issue "Challenges and Perspectives for Swine Viral Vaccines"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 869

Special Issue Editors

Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
Interests: virus vaccine; veterinary virology; molecular cloning
Department of Veterinary and Biomedical Sciences, South Dakota State University, Brookings, SD 57007, USA
Interests: porcine coronaviruses; porcine circoviruses; senecavirus A; emerging viruses
Special Issues, Collections and Topics in MDPI journals
Dr. Anbu Kumar Karuppannan
E-Mail Website
Co-Guest Editor
Vaccine Research Centre, Tamilnadu Veterinary Animal Sciences University, Chennai, India
Interests: virus vaccine immunology

Special Issue Information

Dear Colleagues,

Infections of swine viruses are responsible for significant economic losses in the pork industry worldwide. Vaccination is an important strategy to protect swine against virus diseases.  One of the biggest problems in vaccinology is the rapid genetic changes or the evolution of viruses. Human viral vaccine technologies are rapidly developed, as are the delivery systems and new antigenic epitopes. However, the development of swine viral vaccine either in term of technologies or novel antigenic epitopes which are able to broadly prevent viral infection and induce humoral and cellular immune responses is infrequently studied. Therefore, we would like to compile the challenges and perspectives for swine viral vaccines and the development of swine viral vaccine together with their immunogenicity and efficacies in this Special Issue. 

Dr. Saeng-Chuto Kepalee
Dr. Gun Temeeyasen
Dr. Anbu Kumar Karuppannan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • swine viral vaccines
  • development
  • vaccine technologies
  • prevention

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 9081 KiB  
A Subunit Vaccine Based on the VP2 Protein of Porcine Parvovirus 1 Induces a Strong Protective Effect in Pregnant Gilts
Vaccines 2023, 11(11), 1692; https://doi.org/10.3390/vaccines11111692 - 05 Nov 2023
Viewed by 697
Porcine parvovirus 1 (PPV1) is one of the most prevalent pathogens that can cause reproductive disorder in sows. The VP2 protein of PPV1 is the most important immunogenic protein that induces neutralizing antibodies and protective immunity. Thus, VP2 is considered an ideal target [...] Read more.
Porcine parvovirus 1 (PPV1) is one of the most prevalent pathogens that can cause reproductive disorder in sows. The VP2 protein of PPV1 is the most important immunogenic protein that induces neutralizing antibodies and protective immunity. Thus, VP2 is considered an ideal target antigen for the development of a genetically engineered PPV1 vaccine. In this study, the baculovirus transfer vector carrying the HR5-P10-VP2 expression cassette was successfully constructed with the aim of increasing the expression levels of the VP2 protein. The VP2 protein was confirmed using SDS‒PAGE and Western blot analyses. Electronic microscope analysis showed that the recombinant VP2 proteins were capable of self-assembling into VLPs with a diameter of approximately 25 nm. The immunogenicity of the VP2 subunit vaccine was evaluated in pigs. The results showed that VP2 protein emulsified with ISA 201VG adjuvant induced higher levels of HI antibodies and neutralizing antibodies than VP2 protein emulsified with IMS 1313VG adjuvant. Furthermore, the gilts immunized with the ISA 201VG 20 μg subunit vaccine acquired complete protection against PPV1 HN2019 infection. In contrast, the commercial inactivated vaccine provided incomplete protection in gilts. Therefore, the VP2 subunit vaccine is a promising genetically engineered vaccine for the prevention and control of PPV1. Full article
(This article belongs to the Special Issue Challenges and Perspectives for Swine Viral Vaccines)
Show Figures

Figure 1

Back to TopTop